administration of endotracheal surfactant is potentially the main treatment for neonates suffering from rds (respiratory distress syndrome), which is followed by mechanical ventilation. late and severe complications may develop as a consequence of using mechanical ventilation. in this study, conventional methods for treatment of rds are compared with surfactant administration, use of mechanical...

OBJECTIVE To review well-known aspects of exogenous surfactant therapy, and to discuss controversial points regarding the current state of research. SOURCES Review of the literature, using Medline and Cochrane Database Library, in association with the authors' experience in relation to exogenous surfactant replacement therapy. SUMMARY OF THE FINDINGS The main aspects of surfactant character...

Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in preterm infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. Secondary surfactant deficiency also contributes to acute respiratory morbidity in late-preterm and term neonates with meconium aspiration syndrome, pneumonia/sepsis, and perhaps p...

BACKGROUND: Meconium aspiration syndrome (MAS) is still a condition associated with a high mortality, and many patients require extracorporeal membrane oxygenation (ECMO) as rescue therapy. Beneficial effects of surfactant and perflubron lavage have been reported. However, pure surfactant supplementation has not been proven to be beneficial in the most severe forms of MAS. This study was perfor...

Infant respiratory distress syndrome (IRDS) develops among premature infants due to structural immaturity of the lungs and insufficient production pulmonary surfactant. Nowadays, treatment takes place under conditions intensive care includes oxygen therapy, mechanical ventilation, exogenous supplementation surfactant antenatal corticosteroid therapy. The IRDS, especially may lead complications ...

Surfactant replacement therapy by ‘INSURE’ is a gentle ventilatory approach in preterms with Respiratory Distress Syndrome (RDS) reducing the mortality and is associated with less adverse sequelae than mechanical ventilation. The objective of the present study is to determine the role of surfactant therapy by INSURE in reducing the mortality of preterms with RDS. 59 preterm babies with RDS were...

BACKGROUND In animals with acquired surfactant-deficiency, a recruitment maneuver by increased tidal volumes enhances the effect of exogenous surfactant. In contrast, in the preterm lamb model, hyperinflation early after birth impairs the effect of surfactant prophylaxis. Here we examined whether a lung recruitment maneuver just before surfactant would affect the response to rescue treatment in...

A model is presented of surfactant replacement therapy. An instilled bolus is pushed into the lungs on the first inspiration, coating the airways with a layer of surfactant and depositing some in the alveoli. Layer thickness depends on the capillary number (muU/gamma, where mu, U, and gamma are bolus viscosity, advancing meniscus velocity, and surface tension, respectively). Larger capillary nu...

The benefits of surfactant replacement therapy for neona-tal respiratory distress syndrome (RDS) have been well documented in several randomised trials, and this treatment is now part of routine clinical management of babies with immature lungs. Meta-analysis of data from a large number of babies treated in controlled trials has confirmed lower mortality and reduced incidence of complications ,...